New ways to control the Notch1 protein in T-cell leukemia
New control of oncogene activation in T-cell leukemia
['FUNDING_R01'] · WISTAR INSTITUTE · NIH-11299573
Researchers aim to lower activity of the Notch1 protein to help children and adults with T-cell acute lymphoblastic leukemia.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WISTAR INSTITUTE (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11299573 on ClinicalTrials.gov |
What this research studies
This project builds on lab discoveries in fruit flies and mice showing that a protein called UVRAG can change how the cancer-driving Notch1 protein is broken down. Scientists will use mouse T-ALL models and molecular lab experiments to map how UVRAG and the endo-lysosomal system control Notch1 before it becomes active. The team will look for genes and pathways that could be safer targets than currently toxic Notch1 inhibitors. Findings may point to new drug targets that could make treatment for Notch1-driven T-ALL more effective and less damaging.
Who could benefit from this research
Good fit: Children and adults with T-cell acute lymphoblastic leukemia that is driven by Notch1 alterations would be the most relevant patients for future therapies from this work.
Not a fit: Patients whose leukemia is not driven by Notch1 or those needing immediate clinical treatment are unlikely to gain direct benefit from this laboratory-focused project.
Why it matters
Potential benefit: If successful, this work could identify safer ways to remove or weaken Notch1-driven leukemia cells and lead to better treatments with fewer side effects.
How similar studies have performed: Previous drug attempts to block Notch1 have struggled with toxicity, and targeting UVRAG-mediated degradation is a newer, largely preclinical approach.
Where this research is happening
PHILADELPHIA, UNITED STATES
- WISTAR INSTITUTE — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIANG, CHENGYU — WISTAR INSTITUTE
- Study coordinator: LIANG, CHENGYU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.